Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LeadtoTreat

Financiado

Cerrado

Targeted Nano-formulations for Treatment of MRSA: A multicomponent platform for...

Targeted Nano-formulations for Treatment of MRSA: A multicomponent platform for nano-formulated treatment of resistant microbial infections Many bacteria that cause infectious diseases develop resistance to not only the primary antibiotic treatments available in the clinic but also to drugs of last resort which often require long treatment periods and come with signif... ver más

28/02/2026

SINTEF

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

SINTEF AS No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-03-16

HORIZON-EIC-2021-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2021 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

SINTEF

1.81M€ | Lider

NATIONAL MEDICINES INSTITUTE

344.25K€ | Participante

NANOTAG BIOTECHNOLOGIES GMBH

515.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NAREB Nanotherapeutics for antibiotic resistant emerging bacterial... 13M€ Cerrado

CYCLON HIT NANOCARRIERS FOR THE DELIVERY OF ANTIMICROBIAL AGENTS TO FIG... 4M€ Cerrado

NANOZID DNA nanohydrogel loaded Liposomal formulations for high load... 214K€ Cerrado

NANOTESTS Fabrication and development of nanotoxicology test bacterial... 224K€ Cerrado

PID2020-114347RB-C31 DISEÑO Y SINTESIS DE NANOPARTICULAS MOLECULARES Y BIOMOLECUL... 133K€ Cerrado

CTQ2013-48767-C3-1-R DESARROLLO DE DISPOSITIVOS NANOESTRUCTURADOS COMO PLATAFORMA... 150K€ Cerrado

Duración del proyecto: 47 meses Fecha Inicio: 2022-03-16
Fecha Fin: 2026-02-28

Líder del proyecto

SINTEF AS No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Many bacteria that cause infectious diseases develop resistance to not only the primary antibiotic treatments available in the clinic but also to drugs of last resort which often require long treatment periods and come with significant side effects. At the same time many promising lead compounds with high activity and wide therapeutic windows have failed to progress to clinical trials due to poor solubility, protein absorption or other difficulties in formulation (e.g. low drugability). LeadtoTreat proposes a new solution to these challenges by introduction of a platform for future infection treatment enabling targeted delivery of novel lead compounds with low drugability as well as synergistic combinations of antibiotics and potentiators in a nano-formulation. A novel dual targeting approach, with both direct targeting toward the pathogenic bacteria as well as to areas of inflammation will be employed. This platform technology will be demonstrated by converting a highly active, but insoluble and protein binding, novel compound into targeted nano-formulations for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections with proven in vivo and in vitro safety. Furthermore, LeadtoTreat aims to identify novel synergistic combinations of antibiotics and potentiators and convert these into highly active targeted nano-formulations for treatment of MRSA infections. LeadToTreat will have significant impact on the future treatment of microbial infections, by demonstrating a pathway to co-delivery of synergistic combination of existing antibiotics as well a path way to revitalize the huge library of abandoned low-drugability lead compounds. From an innovation perspective, it is expected to also develop broadly applicable targeting tools (for MRSA, and roadmap for other indications). The project will be managed by SINTEF (Norway) involving Narodowy Instytut Lekow (National Medicine Institute, NMI, Poland) and NanoTag Biotechnologies GmbH (NTB, Germany).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores